CWAM
BIVV

Columbia Wanger Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Columbia Wanger Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$55.6M Buy
1,032,033
+422,091
+69% +$23.1M 0.83% 29
2017
Q3 		$34.8M Buy
609,942
+20,888
+4% +$1.22M 0.51% 83
2017
Q2 		$35.4M Buy
589,054
+116,054
+25% +$6.61M 0.51% 94
2017
Q1 		$25.8M Buy
+473,000
New +$23.3M 0.36% 119

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Columbia Wanger Asset Management's BIVV Position: Q4 2017 in Review

Columbia Wanger Asset Management increased its Bioverativ Inc. Common Stock (BIVV) stake by 69% in Q4 2017, buying an estimated $23.1M and bringing the position to 1,032,033 shares worth $55.6M. The position accounts for 0.83% of the portfolio, ranked #29.

Columbia Wanger Asset Management first reported a position in BIVV in Q1 2017 and has held it in 4 quarters since. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Columbia Wanger Asset Management held 1,032,033 shares of Bioverativ Inc. Common Stock worth $55.6M as of Q4 2017.
  • Columbia Wanger Asset Management bought 422,091 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $23.1M.
  • Bioverativ Inc. Common Stock made up 0.83% of Columbia Wanger Asset Management's portfolio in Q4 2017, its #29 holding.
  • Columbia Wanger Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and has held it in 4 quarters since.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Columbia Wanger Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.